n-methylaspartate has been researched along with Parkinsonian Disorders in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, OY; de Souza Silva, MA; Huston, JP; Petri, D; Schnitzler, A | 1 |
| Kreitzer, AC; Lalive, AL; Parker, PR | 1 |
| Johnson, SW; Wu, YN | 1 |
| Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E | 1 |
| Archer, T; Fredriksson, A | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M; Paganini, F; Stocchi, S | 1 |
| Fleming, SM; Schallert, T; Woodlee, MT | 1 |
| Geser, F; Poewe, W; Wenning, GK | 1 |
| Allbutt, H; Billing, R; Doherty, K; Henderson, J | 1 |
| Emre, M; Hanağasi, HA; Kaptanoglu, G; Sahin, HA | 1 |
| Gmiro, VE; Gorbunova, LV; Lukomskaia, NIa; Rukoiatkina, NI | 1 |
1 review(s) available for n-methylaspartate and Parkinsonian Disorders
| Article | Year |
|---|---|
Should the injured and intact hemispheres be treated differently during the early phases of physical restorative therapy in experimental stroke or parkinsonism?
Topics: Animals; Brain; Dendrites; Disease Models, Animal; Functional Laterality; N-Methylaspartate; Neuroprotective Agents; Parkinsonian Disorders; Receptors, GABA; Recovery of Function; Stroke; Synapses; Time Factors | 2003 |
11 other study(ies) available for n-methylaspartate and Parkinsonian Disorders
| Article | Year |
|---|---|
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Agonists; Functional Laterality; Male; Maze Learning; Mood Disorders; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Wistar; Sensory Gating; Telencephalon | 2015 |
Pathway-Specific Remodeling of Thalamostriatal Synapses in Parkinsonian Mice.
Topics: Adrenergic Agents; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Exploratory Behavior; Functional Laterality; Homeodomain Proteins; Medial Forebrain Bundle; Mice; N-Methylaspartate; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Synapses; Thalamus; Transcription Factors; Tyrosine 3-Monooxygenase; Vesicular Glutamate Transport Protein 2 | 2016 |
Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons.
Topics: Animals; Dopamine; Male; Membrane Potentials; N-Methylaspartate; Neurons; Oxidation-Reduction; Parkinsonian Disorders; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rotenone; Substantia Nigra; Uncoupling Agents | 2011 |
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses | 2011 |
Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Topics: Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Antipsychotic Agents; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Sympatholytics | 2002 |
Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Glutamic Acid; Male; Microdialysis; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Wakefulness | 2002 |
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; N-Methylaspartate; Neuronal Plasticity; Parkinsonian Disorders; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptosomes | 2003 |
Therapeutic strategies in multiple system atrophy.
Topics: Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Anticonvulsants; Autonomic Nervous System Diseases; Cholinergic Agents; Dopamine Agonists; Humans; Multiple System Atrophy; N-Methylaspartate; Palliative Care; Parkinsonian Disorders | 2005 |
Effects of pallidotomy on motor symptoms in an animal model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Female; Functional Laterality; Globus Pallidus; Medial Forebrain Bundle; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Single-Blind Method; Statistics, Nonparametric; Tyrosine 3-Monooxygenase | 2006 |
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Memantine; N-Methylaspartate; Parkinsonian Disorders; Treatment Outcome | 2000 |
[Ability of novel non-competitive glutamate receptor blocking agents to weaken motor disorders in animals].
Topics: Animals; Anticonvulsants; Ataxia; Benzene Derivatives; Catalepsy; Cations; Cyclohexanes; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Haloperidol; Kainic Acid; Mice; N-Methylaspartate; Parkinsonian Disorders; Seizures; Structure-Activity Relationship | 2001 |